Advertisement

Journal of Gastrointestinal Surgery

, Volume 23, Issue 3, pp 477–483 | Cite as

Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms

  • Katherine E. Poruk
  • James Griffin
  • Martin A. Makary
  • Jin He
  • John L. Cameron
  • Matthew J. Weiss
  • Laura D. Wood
  • Michael Goggins
  • Christopher L. WolfgangEmail author
Original Article
  • 123 Downloads

Abstract

Background

Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions to the development of pancreatic adenocarcinoma. We determined if non-O blood groups are more common in patients with IPMN and if blood group is a risk factor for progression to invasive pancreatic cancer among patients with IPMN.

Methods

The medical records were reviewed of all patients undergoing resection of an IPMN at Johns Hopkins Hospital from June 1997 to August 2016. Potential risk factors of high-grade dysplasia and associated adenocarcinoma were identified through a multivariate logistic regression model.

Results

Seven hundred and seventy-seven patients underwent surgical resection of an IPMN in which preoperative blood type was known. Sixty-two percent of IPMN patients had non-O blood groups (vs. 57% in two large US reference cohorts, P = 0.002). The association between non-O blood group was significant for patients with IPMN with low- or intermediate-grade dysplasia (P < 0.001), not for those with high-grade dysplasia (P = 0.68). Low- and intermediate-grade IPMNs were more likely to have non-type O blood compared to those with high-grade IPMN and/or associated invasive adenocarcinoma (P = 0.045). Blood type O was an independent predictor of having high-grade dysplasia without associated adenocarcinoma (P = 0.02), but not having associated invasive cancer (P = 0.72). The main risk factor for progression to invasive cancer after surgical resection was IPMN with high-grade dysplasia (P = 0.002).

Conclusion

IPMN patients are more likely to have non-O blood groups than controls, but type O blood group carriers had higher odds of having high-grade dysplasia in their IPMN. These results indicate blood group status may have different effects on the risk and progression of IPMNs.

Keywords

ABO Blood type IPMN Intraductal papillary mucinous neoplasm High-grade dysplasia Pancreatic cancer Pancreatic ductal adenocarcinoma 

Notes

Funding

Funding for this study was provided by NIH grants CA126607-061 (KEP), the Sol Goldman Cancer Research Grant (KEP), and CA62924, CA176828. MG is the Sol Goldman Professor of Pancreatic Cancer Research.

The research was supported by funds from Susan Wojcicki and Dennis Troper.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Edgren G, Hjalgrim H, Rostgaard K, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol 2010; 172(11):1280–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009; 101(6):424–31.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009; 41(9):986–90. Epub 2009 Aug 2.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Petersen GM, Amundadottir L, Fuchs CS, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics 2010; 42:224–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wolpin BM, Rizzato C, Kraft P, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. 2014; 46(9):994–1000.Google Scholar
  6. 6.
    Childs EJ, Chaffee KG, Gallinger S, et al. Association of common susceptibility variants of pancreatic cancer in higher risk patients: A PACGENE study. Cancer Epidemiol Biomarkers Prev 2016.Google Scholar
  7. 7.
    Childs EJ, Mocci E, Campa D, et al. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. 2015; 47(8):911–6.Google Scholar
  8. 8.
    Kim SC, Park KT, Lee YJ, et al. Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center. J Hepatobiliary Pancreat Surg 2008; 15(2):183–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Lee SY, Lee KT, Lee JK, et al. Long-term follow up results of intraductal papillary mucinous tumors of pancreas. J Gastroenterol Hepatol 2005; 20(9):1379–84.CrossRefPubMedGoogle Scholar
  10. 10.
    Nagai K, Doi R, Kida A, et al. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World J Surg 2008; 32(2):271–8; discussion 279–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Nara S, Onaya H, Hiraoka N, et al. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases. Pancreas 2009; 38(1):8–16.CrossRefPubMedGoogle Scholar
  12. 12.
    Sadakari Y, Ienaga J, Kobayashi K, et al. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. Pancreas 2010; 39(2):232–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Ohashi K MY, Takekoshi T, et al. Four cases of mucin producing cancer of the pancreas on specific findings of the papilla of Vater Prog Dig Endosc 1982; 20:348–351.Google Scholar
  14. 14.
    Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6(1–2):17–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12(3):183–97.CrossRefPubMedGoogle Scholar
  16. 16.
    Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002; 123(5):1500–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004; 239(5):678–85; discussion 685–7.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rezaee N, Barbon C, Zaki A, et al. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB (Oxford) 2016; 18(3):236–46.CrossRefGoogle Scholar
  19. 19.
    Crippa S, Bassi C, Salvia R, et al. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. Gut 2016:epub 2016/01/09.Google Scholar
  20. 20.
    Sahora K, Mino-Kenudson M, Brugge W, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg 2013; 258(3):466–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Ridtitid W, DeWitt JM, Schmidt CM, et al. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes. Gastrointest Endosc 2016:epub 2016/02/26.Google Scholar
  22. 22.
    Yamada S, Fujii T, Murotani K, et al. Comparison of the international consensus guidelines for predicting malignancy in intraductal papillary mucinous neoplasms. Surgery 2016; 159(3):878–84.CrossRefPubMedGoogle Scholar
  23. 23.
    Mukewar S, de Pretis N, Aryal-Khanal A, et al. Fukuoka criteria accurately predict risk for adverse outcomes during follow-up of pancreatic cysts presumed to be intraductal papillary mucinous neoplasms. Gut 2016.Google Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2018

Authors and Affiliations

  • Katherine E. Poruk
    • 1
  • James Griffin
    • 1
  • Martin A. Makary
    • 1
  • Jin He
    • 1
  • John L. Cameron
    • 1
  • Matthew J. Weiss
    • 1
  • Laura D. Wood
    • 2
  • Michael Goggins
    • 2
    • 3
  • Christopher L. Wolfgang
    • 1
    Email author
  1. 1.Department of SurgeryJohns Hopkins HospitalBaltimoreUSA
  2. 2.Department of PathologyJohns Hopkins HospitalBaltimoreUSA
  3. 3.Department of Oncology and Medicine, the Sol Goldman Pancreatic Cancer Research CenterJohns Hopkins HospitalBaltimoreUSA

Personalised recommendations